HIV Preexposure Prophylaxis in the U.S. — Recent Trends

Using a national prescription database, CDC investigators describe patterns of PrEP use from 2013 through 2023.

Since July of 2012 — when preexposure prophylaxis (PrEP) medication for preventing HIV infection (branded TDF/FTC) was first approved by the FDA — branded TAF/FTC, generic TDF/FTC, and injectable cabotegravir (CAB-LA) have also been approved. Now, CDC investigators have analyzed PrEP prescriptions using a national database that enables single-patient tracking of prescriptions and demographic data.

From 2013 through 2023, a total of 1,126,878 persons (89% male) received PrEP prescriptions, with the annual number of PrEP users increasing from 10,281 to 505,730. Use of branded TDF/FTC increased from 2013 until 2019, but then declined when branded TAF/FTC became available, followed by generic TDF/FTC. As of December 2019, generic TDF/FTC was the…

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

HIV Preexposure Prophylaxis in the U.S. — Recent Trends

Topics

Reviewing Author